Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Key considerations before the dust settles on a mega merger

This article was originally published in Scrip

Executive Summary

With companies carving off certain assets in their portfolios, both sellers and buyers are faced with the challenge of how to divest if they're selling, or integrate if they're buying that particular asset. With the ink only just dry on the deal, how well the company divests or integrates an asset can often make or break the success of the transaction, a factor the pharma sector understands more than most.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC024667

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel